When it comes to CHR’s media exposure, February was a truly remarkable month. CHR was all over the world mentioned in print media in conjunction with a paper that announced the first successful in vitro culture of primordial oocytes to maturity. CHR’s Director of Laboratories and Senior Scientist, David F. Albertini, PhD, collaborated with Scottish investigators from the University of Edinburgh on the project. This is only one of many ongoing collaborations between CHR investigators and prominent academic institutions all over the world.
ABC News featured a lengthy article on older and older women having children, extensively quoting Norbert Gleicher, MD, CHR’s Medical Director and Chief Scientist. ACOG’s Today’s Headlines picked up the story. Other media quoted David H. Barad, MD, MS, CHR’s Director of Clinical ART and Senior Scientist in reference to ovarian rejuvenation procedures and Vitaly A. Kushnir, MD, CHR’s Director of Fertility Preservation and Continuous Medical Education and Associate Scientist, in reference to a recent CHR publication, where he was lead author, that confirmed lower pregnancy rates with frozen than fresh donor oocytes [Kushnir et al., The national outcome data on fresh versus cryopreserved donor oocytes. J Ovarian Res 2018;11(1):2; see also the lead article on egg donation].
We in this issue of the VOICE are also pleased to present CHR’s cumulative IVF outcomes for 2017 with attached commentary and explanations.
In this issue, we cover:
Norbert Gleicher, MD, leads CHR’s clinical and research efforts as Medical Director and Chief Scientist. A world-renowned specialist in reproductive endocrinology, Dr. Gleicher has published hundreds of peer-reviewed papers and lectured globally while keeping an active clinical career focused on ovarian aging, immunological issues and other difficult cases of infertility.
DISCOVER YOUR TREATMENT OPTIONS
